



A member of the dms health group

November 1, 2004

Operations office:	Corporate office:
109 S. Petro Avenue	2101 N. University Drive
Sioux Falls, SD 57107	Fargo, ND 58102
Phone: 605-330-9060	Phone: 701-237-9073
800-333-0365	800-437-4628
Fax: 877-595-8108	Fax: 800-848-0990

www.dmshg.com

U.S. Nuclear Regulatory Commission
Region III
801 Warrenville Road
Lisle, IL 60532-4351

To Whom It May Concern:

Attached please find diagrams for a new storage location, which we request to be added to our NRC license #40-32477-01. There are site, and building diagrams attached.

The new storage location is located at 11600 96th Avenue North, Maple Grove, MN 55369. This facility is located in an industrial park. The adjoining suite in the same building will be treated as fully occupied offices. The outside areas are treated as parking lot. There will be outside mobile medical coach parking in the indicated shelters. Security for all vehicles at the loading dock and shelter bays will be provided by the key and crypto-locks on the mobile units. There will be sufficient shielding installed as necessary to ensure that there will be no exposure rates above 2 millirem/hour or annual exposures above 100 millirem per year in any of the adjacent areas.

We request the ability to receive, store, dispatch and use (for instrument calibration or QC only) any radioactive material permitted under 10CFR35.65, 35.100, and 35.200 at this new storage location. The site would have to be occupied by licensee's trained personnel to be able to receive, use (calibration or QC only) or dispatch unit doses permitted under 10CFR35.100 or 35.200. Receipt will be handled only if there is a mobile unit present at the site. Receipt will not be permitted in the absence of a mobile medical unit, as there will be no hot lab, or waste storage. There will be no generator usage or radioactive gas use at this storage site or on board any of the mobile medical units.

We also request to add Jihad M. Khalil, M.D. as an authorized user for 35.200 restricted to nuclear cardiology. Attached is preceptor and training information as well as NRC License # 40-12378-01 listing Dr. Khalil as an authorized user.

If you have any questions please contact me at 800-333-0365 extension 117.


Sincerely,

Traci Hollingshead, CNMT
Radiation Safety Officer

OCT.13'2004 14:20 763 424 5822

Loucks Associates

#7537 P.001/001



To: Michael Alsten ^{Fax 425-4709} 763-315
 1947

Post-It® Fax Note 7671		Date 10/12	# of pages 1
To SANORA HUNTEN	From Mike Flegel		
Co./Dept. LANDCOR	Co. LOUCKS		
Phone # 315-01818	Phone # 763-424-5505		
Fax # 315-0817	Fax # 763-424-5822		

ASSOCIATES IN MEDICAL PHYSICS,
NATIONAL MEDICAL PHYSICS CONSULTING GROUP



NATIONAL OFFICE:
5288 TRANSPORTATION BLVD.
CLEVELAND, OH 44125

www.medphysics.com

PHONE: (216) 663-7000
FAX: (216) 581-4361
V M: (800) 709-4855

This is to certify that

Jihad Khalil, M.D.

has completed all requirements for the Nuclear Physician Licensing Course. Associates in Medical Physics, LLC designates this continuing medical education activity for 50 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

Dates attended:

February 9-13, 2004

Director of Training

February 13, 2004

Date

Associates in Medical Physics, LLC is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER Jihad Khalil, M.D.	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
--	--

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATES OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	50 Hour Nuclear Physician Licensing Course held by Associates in Medical Physics, LLC, in Atlanta, Georgia on the following dates:	20	
b. RADIATION PROTECTION	February 9-13, 2004	12	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY		6	
d. RADIATION BIOLOGY		4	
e. RADIOPHARMACEUTICAL CHEMISTRY		8	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	HOW USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME

Jihad Khalil, M.D.

STREET ADDRESS

CITY

STATE

ZIP CODE

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1. Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
2. Collaboration in dose calibration and actual administration of dose in the patient including calculation of the radiation dose, related measurements and plotting of data.
3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS <i>(Additional information or comments may be submitted in duplicate on separate sheets.) D</i>
	Thyroid scan	X	
	Thyroid uptake	X	
	Lung perfusion scan	X	
	Krypton ventilation study	X	
	Aerosol ventilation scan	X	
	Pertal flow scan	X	
	Brain scan	X	
	Liver/spleen scan	X	
	Bone scan	X	
	Gastroesophageal study	X	
	LeVeen shunt study	X	
	Cystogram	X	
	Dactylocystogram	X	
	Cardiac perfusion scan	X	
	Cardiac stress ventriculogram	X	
	Cardiac rest ventriculogram	X	
	Gallium scan	X	

PROPOSED PHYSICIAN USER **Jiha Khalil, M.D.**

PRECEPTOR STATEMENT (CONTINUED)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Sodium)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	X	
P-32 (Cobalt)	INTRACAVITARY TREATMENT	X	
I-131	TREATMENT OF THYROID CARCINOMA	X	
	TREATMENT OF HYPERTHYROIDISM	X	
Au-199	INTRACAVITARY TREATMENT	X	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	X	
	INTRACAVITARY TREATMENT	X	
I-125 or Ir-192	INTERSTITIAL TREATMENT	X	
Co-60 or Cs-137	TELE THERAPY TREATMENT	X	
Sr-90	TREATMENT OF EYE DISEASE	X	
	RADIOPHARMACEUTICAL PREPARATION	X	
Mo-99/ Tc-99m	GENERATOR	1	
Sn-113/ In-113m	GENERATOR	X	
Tc-99m	REAGENT KITS	1	
Other	ALUMINA TESTING	X	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
Associates in Medical Physics, LLC Presented in Atlanta, GA	February 9-13, 2004	2

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:


a. NAME OF SUPERVISOR
Frank Bloe

b. NAME OF INSTITUTION
Associates in Medical Physics, LLC

c. MAILING ADDRESS
5288 Transportation Boulevard

d. CITY
Cleveland, Ohio 44125

5. MATERIALS LICENSE NUMBER(S)
34-26645-02

6. PRECEPTOR'S SIGNATURE


7. PRECEPTOR'S NAME (Please type or print)
Frank Bloe, DABSNM, DABMP

8. DATE
February 13, 2004

ASSOCIATES IN MEDICAL PHYSICS, LLC

THIS CERTIFIES THAT

Jihad Khalil, M.D.

**HAS SUCCESSFULLY COMPLETED ALL REQUIREMENTS
FOR THE**

**50 HOUR
NUCLEAR PHYSICIAN LICENSING COURSE**

**AND IS HEREBY AWARDED THIS
CERTIFICATE OF COMPLETION**

ON THIS Thirteenth DAY OF February, 2004



DIRECTOR OF TRAINING

Sioux Valley Hospital- University of South Dakota.
Department of Nuclear Medicine
1100 S. Euclid Avenue
Sioux Falls, SD 57117

To Whom It May Concern:

This letter is to affirm that Jihad M. Khalil, M.D; FACC obtained supervised nuclear medicine, nuclear cardiology, clinical and work experience in our department of nuclear medicine during his practice at Heart Partners, Sioux Valley Clinic from May 2003 - June 2004.

The clinical experience included active participation in the following procedures:

Over 170 Cardiolute(Tc-99m sestamibi) stress/rest perfusion studies.

Over 50 Thallium stress/rest imaging procedures.

Over 10 Thallium rest/redistribution viability studies.

157 Myoview (Tc-99m transformin) stress/rest.

124 pharmacological stress/rest imaging.

Over 300 Ejection Fraction calculation procedures.

Over 300 wall motion evaluation studies.

Over 50 Cardiac Catheterization /muocardial perfusion correlation cases.

Most of those cases were actual patients of Dr Khalil or patients of members of his group who he had the clinical experience of Knowing the history and physical exam of those patients, selected and supervised the administration of the proper radiopharmaceutical and dose.

A log of the cases mentioned above is available upon request.

Affidavits of didactic radiation safety training etc. totaling 50 hours as required per Non-agreement states are enclosed.

Concurrent with clinical experience was supervised work experience, this include but not limited to ordering, receiving, calibrting the dose caliber, checks for proper operation, calculating and preparing patient doses.

Dr Khalil's supervised clinical and work experience during this period total 750 hours.

Sincerely,



Fred C. Lovrien, M.D; FACP

Nuclear Physician.

Department Chairman, Nuclear Medicine.

Clinical Professor, USD Medical School.

THE AMERICAN BOARD OF INTERNAL MEDICINE

INCORPORATED 1936

ATTESTS THAT

Jihad Moneer Khalil

HAS MET THE REQUIREMENTS OF THIS BOARD AND IS HEREBY

CERTIFIED FOR THE PERIOD 1997 THROUGH 2007

AS A DIPLOMATE IN

INTERNAL MEDICINE

Mark A. Kelly
CHAIR
John C. Casper
CHIEF OF STAFF
R. F. LeBeand
SECRETARY/TREASURER
Henry R. Macomber
PROFESSOR
James O. Armitage
William H. Beckett
John A. ...

Arthur Casper
David R. Dantzer
Mark Feldman
Alan M. Fogelman
Michael Khalil
Paul ...
Manjiv ...



Ralph D. Horwitz *Robert W. Macdonald*
Nancy S. Johnson Jr. *Janet Vanfossen*
Tom Lyell *D. W. Powell*
Ronald V. Lopez *James L. Reimster*
Jeanette Meadmon *Ally ...*
Anne Moore *Doris P. Zepic*

THIS IS YOUR 2004 LICENSE
Please detach and retain the attached card for your record of licensure.

SOUTH DAKOTA
STATE BOARD OF MEDICAL EXAMINERS
Certificate of Registration

SD License Number **4777**
This is to certify that


Jihad Khalil, MD

Jihad Khalil, MD
SVC - Heart Partners
1305 W 18th St
Sioux Falls, SD 57105-0401

is registered to practice Medicine or Osteopathy as provided by
the laws of the State of South Dakota

Void after February 28, 2005

Richard L. Porter, MD, Secretary



Initiated by
2004

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Sioux Valley Hospital dba Sioux Valley Hospital University of South Dakota Medical Center</p> <p>2. 1305 West 18th Street P.O. Box 5039 Sioux Falls, South Dakota 57117-5039</p>	<p>In accordance with facsimiles received April 12, 2004, July 12, 2004, July 19, 2004</p> <p>3. License number 40-12378-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2004</p> <hr/> <p>5. Docket No. 030-03249 Reference No.</p>
---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 800 millicuries
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed
F. Calcium-45	F. Any	F. 10 millicuries
G. Yttrium-90	G. Any	G. 800 millicuries
H. Strontium-90	H. Sealed sources (BEBIG Model Sr0.S03 and AEAT SICW Series)	H. Not to exceed 5 millicuries per source and 800 millicuries total.
I. Iridium-192, as permitted by 10 CFR 35.600	I. Sealed sources (Nucletron Model No. 105.002, manufactured by Mallinckrodt Medical BV or AEA Technology, Inc.)	I. 2 sources not to exceed 12 curies each.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
40-12378-01

Docket or Reference Number
030-03249

Amendment No. 60

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. Medical use described in 10 CFR 35.400 and, for Cesium-137, calibration of licensee's survey meters and personnel dosimeters.
- E. In vitro studies.
- F. and G. Research involving human subjects as described in 10 CFR 35.6.
- H. Notwithstanding the requirements of 10 CFR 35.400, for use in Novoste A1000 Series transfer devices for intravascular brachytherapy.
- I. One source for medical use, as permitted by 10 CFR 35.600, in a Nucletron MicroSelectron-HDR Model 105.999 remote afterloading brachytherapy device. One source (not to exceed 12 curies while stored pending installation) in a shipping container for source replacement.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 1305 West 18th Street, Sioux Falls, South Dakota.
- 11. The Radiation Safety Officer for this license is Fred C. Lovrien, M.D.
- 12. The following individuals are authorized users:

Material and Use

Thomas M. Cink, M.D.	35.100, 35.200, 35.300, 31.11, and Yttrium-90
Robert P. DeClark, M.D.	35.300, 31.11, and Yttrium-90 restricted to radioimmunotherapy research
Andrew I. Soye, M.D.	35.100, 35.200, 35.300, 31.11, and Yttrium-90
Bert W. Larson, M.D.	35.100, 35.200, 35.300, 31.11, and Yttrium-90
Kirsten R. Erickson, M.D.	35.400, Strontium-90 for intravascular brachytherapy, and Iridium-192 for uses in a high dose rate remote afterloader unit
Fred Clinton Lovrien, M.D.	35.100, 35.200, 35.300, Calcium-45, and Yttrium-90

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
40-12378-01

Docket or Reference Number
030-03249

Amendment No. 60

Material and Use

Larry R. Past, M.D.	35.300, 35.400, Strontium-90 for intravascular brachytherapy, and Iridium-192 for uses in a high dose rate remote afterloader unit
John F. Griffin, M.D.	35.400, Strontium-90 for intravascular brachytherapy, and Iridium-192 for uses in a high dose rate remote afterloader unit
Frank M. Grund, M.D.	35.100 and 35.200
Kathleen L. Schneekloth, M.D.	35.300, 35.400, Strontium-90 for intravascular brachytherapy, and Iridium-192 for uses in a high dose rate remote afterloader unit
David C. Hickey, M.D.	35.100, 35.200, 35.300, 31.11, Calcium-45, and Yttrium-90
Steven C. McGraw, M.D.	35.300, 35.400, Strontium-90 for intravascular brachytherapy, and Iridium-192 for uses in a high dose rate remote afterloader unit
Thomas A. Schultz, M.D.	35.100, 35.200, and 35.300
Jihad M. Khalil, M.D.	35.200 restricted to nuclear cardiology

13. The therapy physicists for this license are Charles M. Carver, M.S., Jeffrey P. Masten, M.S., and Richard J. Massoth, Ph.D.
14. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.
15. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

40-12378-01

Docket or Reference Number

030-03249

Amendment No. 60

- C. In the absence of a certificate from a transferor indicating that a leak test has been made, within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- D. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- E. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- F. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, 611 Ryan Plaza Drive, Suite 400, Arlington, Texas 76011; ATTN: Director, Division of Nuclear Materials Safety. The report shall specify the source involved, the test results, and corrective action taken.
- G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
17. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
40-12378-01Docket or Reference Number
030-03249

Amendment No. 60


18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 23, 1994
- B. Letter dated September 10, 1999
- C. Letter dated May 1, 2000, excluding modification to Quality Management Program (QMP)
- D. Facsimile dated June 7, 2001
- E. Letter dated July 18, 2001
- F. Letter dated December 20, 2001
- G. Letter dated July 15, 2002
- H. Letter dated June 30, 2003
- I. Letter dated August 22, 2003

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: OCT 8 2004

By: _____

Rachel S. Browder, Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011

FedEx | Ship Manager | Label 7919 7618 0264

From: Origin ID: (605)330-9060
Bernice Norton
DMS IMAGING
109 SOUTH PETRO AVENUE
SIOUX FALLS, SD 57107



Ship Date: 09NOV04
Actual Wgt: 1 LB
System#: 5867540/INET2000
Account#: S *****

REF: Traci Hollingshead



Delivery Address Bar Code


SHIP TO: (800)333-0365 **BILL SENDER**
Region III
U.S. Nuclear Regulatory Commission
801 Warrenville Road

Lisle, IL 605324351

PRIORITY OVERNIGHT

WED

Deliver By:
10NOV04



TRK# 7919 7618 0264

FORM 0201

ORD A2

60532 -IL-US

XH ENLA

